Cargando…

Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis

OBJECTIVES: Direct toxic effects of transthyretin amyloid in patient plasma upon cardiomyocytes are discussed. However, no data regarding the relevance of this putative effect for clinical outcome are available. In this monocentric prospective study, we analyzed cellular hypertrophy after phenylephr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hein, Selina, Furkel, Jennifer, Knoll, Maximilian, aus dem Siepen, Fabian, Schönland, Stefan, Hegenbart, Ute, Katus, Hugo A., Kristen, Arnt V., Konstandin, Mathias H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055573/ https://www.ncbi.nlm.nih.gov/pubmed/33481097 http://dx.doi.org/10.1007/s00392-020-01801-y

Ejemplares similares

Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis
por: Hein, Selina J, et al.
Publicado: (2021)

Wild-type transthyretin amyloidosis in female patients
por: Kristen, Arnt V, et al.
Publicado: (2015)

Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis
por: Arenja, Nisha, et al.
Publicado: (2019)

Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
por: Siepen, Fabian aus dem, et al.
Publicado: (2015)

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia
por: Dittrich, Tobias, et al.
Publicado: (2019)

Prognosis of light chain amyloidosis: a multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy
por: Aurich, Matthias, et al.
Publicado: (2023)

Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis
por: Ochs, Marco M., et al.
Publicado: (2017)

Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis
por: Hoerbrand, Isabel A., et al.
Publicado: (2022)

T1 mapping: useful for treatment monitoring in patients with senile systemic amyloidosis?
por: dem Siepen, Fabian aus, et al.
Publicado: (2014)

Non-invasive risk stratification of patients with TTR amyloidosis
por: Scherer, Katrin A, et al.
Publicado: (2013)

Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms
por: Korosoglou, Grigorios, et al.
Publicado: (2021)

Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2022)

Comparison of late gadolinium enhancement patterns in different forms of cardiac amyloidosis
por: Kammerer, Rebekka, et al.
Publicado: (2013)

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2023)

Thickness of the midventricular left ventricular wall is predictive of survival in different forms of cardiac amyloidosis
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2020)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Campbell, Courtney M., et al.
Publicado: (2022)

Non-invasive measurement of myocardial extracellular volume using T1 mapping as a novel biomarker of diffuse fibrosis in dilated cardiomyopathy
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

Cardiac magnetic resonance strain imaging in systemic light chain amyloidosis
por: Andre, Florian, et al.
Publicado: (2014)

C-MORE: A high-content single-cell morphology recognition methodology for liquid biopsies toward personalized cardiovascular medicine
por: Furkel, Jennifer, et al.
Publicado: (2021)

Green tea halts progression of cardiac transthyretin amyloidosis: an observational report
por: Kristen, Arnt V., et al.
Publicado: (2012)

Assessment of myocardial strain in patients with myocarditis by cardiac magnetic resonance imaging
por: Andre, Florian, et al.
Publicado: (2014)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Diffuse myocardial fibrosis in early forms of dilated cardiomyopathy: insights from T1 mapping cardiovascular magnetic resonance
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

Right ventricular function in dilated cardiomyopathy: relation to location of focal myocardial fibrosis
por: Abdelrazek, Mohamed A, et al.
Publicado: (2013)

MR-Neurography of the sural nerve in patients with hereditary amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2015)

Extracellular volume assessed by CMR T1-mapping correlates with histologically determined amount of diffuse fibrosis in DCM
por: aus dem Siepen, Fabian, et al.
Publicado: (2014)

Quantitative MR-neurographic parameters can determine and specify nerve injury in amyloid related polyneuropathy
por: Kollmer, Jennifer, et al.
Publicado: (2015)

MRI detected mass decrease in patients with amyloidosis after treatment with green tea: a one year follow-up study
por: Buss, Sebastian, et al.
Publicado: (2012)

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement
por: Berghaus, Natalie, et al.
Publicado: (2022)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

Multidisciplinary Approaches for Transthyretin Amyloidosis
por: Koike, Haruki, et al.
Publicado: (2021)

Hereditary transthyretin amyloidosis overview
por: Manganelli, Fiore, et al.
Publicado: (2020)

Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)
por: Yilmaz, A., et al.
Publicado: (2021)

EGCG-Mediated Protection of Transthyretin Amyloidosis by Stabilizing Transthyretin Tetramers and Disrupting Transthyretin Aggregates
por: Zou, Huizhen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bp0jk5eufs31bcrasrdvtdgq23